cPLA₂α-arkiv - BioStock

CoeginPhaseI

Phase I/II data boosts Coegin Pharma

8 April, 2022

Tore Duvold, CEO Coegin Pharma

Coegin Pharma on the cusp of initiating COAK Study

15 September, 2021

Coegin Pharma – generating value and reducing risk in 2021

7 May, 2021

Coegin Pharma submits clinical study application

12 March, 2021

Coegin Pharma’s clinical development in actinic keratosis

25 February, 2021

Coegin Pharma brings new vision for cancer treatment

29 January, 2021

Status report Coegin Pharma – A new approach to cancer therapy

18 December, 2020